Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses findings from the Phase I/II BRUIN trial (NCT03740529), investigating the efficacy of the reversible BTK inhibitor (BTKi) pirtobrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). The trial showed promising preliminary efficacy of this drug, with a 50% overall response rate (ORR) and median progression-free survival (PFS) of 15.6 months in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video Pirtobrutinib in R/R MZL: insights from the BRUIN trial online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 29 January 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 85 once and liked it 2 people.